Abstract
Most protocols of gene therapy clinical trials are based on immunotherapy strategies with genetically modified tumor vaccines (GMTV). The major issue when designing GMTV is gene delivery system; RV proven to be very useful for ex vivo transduction of therapeutic genes. The advantages of RV include: easy manipulation of small viral genome, stable integration of transduced gene and safety. Most frequently, Gibbon Ape Leukemia Virus (GaLV) and Amphotropic Murine Leukemia Virus (AMuLV) envelope proteins are used to pseudotype RV-based vectors. Such vector pseudotypes infect target cells by their specific receptors: PiT1 and PiT2, respectively. Both receptors belong to the same family’, and despite high degree homology, no cross interference is observed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
